Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Predictmedix Inc.

PMEDFPNK
Healthcare
Medical - Devices
$0.04
$0.005(14.80%)
U.S. Market opens in 14h 45m

Predictmedix Inc. Fundamental Analysis

Predictmedix Inc. (PMEDF) shows weak financial fundamentals with a PE ratio of -8.56, profit margin of 0.00%, and ROE of 1.24%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.06

Areas of Concern

ROE1.24%
Operating Margin0.00%
Cash Position4.24%
Current Ratio0.34
We analyze PMEDF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 52.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
52.1/100

We analyze PMEDF's fundamental strength across five key dimensions:

Efficiency Score

Weak

PMEDF struggles to generate sufficient returns from assets.

ROA > 10%
-2.43%

Valuation Score

Excellent

PMEDF trades at attractive valuation levels.

PE < 25
-8.56
PEG Ratio < 2
-0.06

Growth Score

Weak

PMEDF faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

PMEDF shows balanced financial health with some risks.

Debt/Equity < 1
0.00
Current Ratio > 1
0.34

Profitability Score

Weak

PMEDF struggles to sustain strong margins.

ROE > 15%
123.63%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is PMEDF Expensive or Cheap?

P/E Ratio

PMEDF trades at -8.56 times earnings. This suggests potential undervaluation.

-8.56

PEG Ratio

When adjusting for growth, PMEDF's PEG of -0.06 indicates potential undervaluation.

-0.06

Price to Book

The market values Predictmedix Inc. at -12.65 times its book value. This may indicate undervaluation.

-12.65

EV/EBITDA

Enterprise value stands at -13.03 times EBITDA. This is generally considered low.

-13.03

How Well Does PMEDF Make Money?

Net Profit Margin

For every $100 in sales, Predictmedix Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $1.24 in profit for every $100 of shareholder equity.

1.24%

ROA

Predictmedix Inc. generates $-2.43 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.43%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

PMEDF converts -7.08% of its market value into free cash.

-7.08%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-8.56

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.06

vs 25 benchmark

P/B Ratio

Price to book value ratio

-12.65

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.34

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.24

vs 25 benchmark

ROA

Return on assets percentage

-2.43

vs 25 benchmark

ROCE

Return on capital employed

1.19

vs 25 benchmark

How PMEDF Stacks Against Its Sector Peers

MetricPMEDF ValueSector AveragePerformance
P/E Ratio-8.5629.45 Better (Cheaper)
ROE123.63%779.00% Weak
Net Margin0.00%-24930.00% (disorted) Weak
Debt/Equity0.000.26 Strong (Low Leverage)
Current Ratio0.344.65 Weak Liquidity
ROA-243.13%-19333.00% (disorted) Weak

PMEDF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Predictmedix Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ